Inceptive is a privately-held, venture capital-backed company that designs RNA molecules using large-scale deep learning and high-throughput experiments. The company aims to improve the lives of billions of people worldwide by developing powerful biological software to create novel and accessible medicines and biotechnologies.
Syros Pharmaceuticals Isomorphic Labs Insitro Recursion Inceptive EvolutionaryScale
Inceptive has offices in the following locations:
Inceptive has approximately 40 employees, including:
Inceptive's executive team includes:
Inceptive has raised a total of $100 million in funding as of its Series A round in October 2023. The company's investors include:
Inceptive offers consulting and engineering services, helping businesses with digital transformation and startup solutions. They specialize in:
Inceptive Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system.
We are creating tools to develop increasingly powerful biological software for the design of novel, broadly accessible medicines and biotechnologies previously out of reach.
Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning life's languages to improve the lives of billions of people around the world, apply here. info@inceptive.life +1 (650) 507-4490 Wet research and development: 3440 Hillview Ave, D100, Palo Alto, CA, 94304, USA Dry research and development: Planet Earth.
https://beincrypto.com/pharma-company-create-drugs-ai/
We use cookies to improve your experience.
Accept News Rankings Learn Bonus Hunter Advertise Learn-to-Earn Newsletters Web3 Jobs
ENGLISH Bitcoin BTC $581102.82% Ethereum ETH $3059.592.85% Tether USDT $0.9998490.04% BNB BNB $524.885.26% Solana SOL $142.596.06% USDC USDC $0.9997460.03% Lido Staked Ether STETH $3055.922.78% XRP XRP $0.4479295.23% Toncoin TON $7.544.01% Dogecoin DOGE $0.112776.49% Edit See More Home/ Markets News Report Former Google Employee Raises $100 Million to Bring AI to Big Pharma 2 mins David-Thomas.jpg By David Thomas 7 September 2023, 10:15 GMT+0000 Geraint-Price.jpg Updated by Geraint Price 7 September 2023, 10:15 GMT+0000 Share on Twitter Share on Email Share on Linkedin Share on Google News In Brief Inceptive, a Palo Alto-based biotech startup, has secured $100 million to develop unique vaccine proteins using AI. The startup aims to replicate the success of mRNA drugs, similar to COVID-19 vaccines, with AI-developed proteins. Backed by Andreessen Horowitz and Nvidia's NVentures, Inceptive aims to impact AI's role in drug discovery. PROMO Former Google Employee Raises $100 Million to Bring AI to Big Pharma Palo Alto-based biotech startup Inceptive has raised $100 million to develop unique vaccine proteins using artificial intelligence (AI). The company hopes to replicate the success of messenger-RNA (mRNA) drugs similar to the vaccines used to fight COVID-19.
The company’s CEO, Jakob Uszkoreit, a former Google senior staff software engineer who pioneered work on large-language models, says the company will license new proteins its AI develops for clinical trials. There are already 310 pilots occupying the continuum from pre-clinical to clinical trials.
Inceptive Wants Proteins Designed by AI Algorithms to Instruct Human Body Cells According to Uszkoreit, the new drugs will instruct cells in the human body to execute instructions similar to how a computer runs code. By the decade’s end, there will be about 700 mRNA-based drugs.
“We want to maximize the positive impact of this type of work in AI,” Uszkoreit said.
The CEO’s time at Google involved developing machine-learning tools to understand natural language. His work helped Google’s DeepMind create an algorithm to predict the structure of almost every known protein.
Proteins are chains of chemical compounds called amino acids that twist into shapes depending on their purpose. The human body naturally produces around 20,000 proteins for, among other things, digesting food and transporting oxygen.
Biotech Inceptive to create proteins from an AI aglorithm.Six protein shapes a DeepMind’s AI algorithm created | Source: New York Times Read here about how novel products are using AI automation to streamline workflows.
Inceptive has the backing of Silicon Valley venture capitalists (VCs) Andreessen Horowitz and Nvidia Corporation’s venture capital arm, NVentures. The latter invested $50 million in another drug discovery company, Recursion Pharmaceuticals, based in Utah.
Inceptive’s deal with Nvidia will give the chipmaker an equity stake and avail its cutting-edge tools to the Palo Alto-based startup company. Other notable firms in the AI-biotech space include Insilico, a company in the mid-stage clinical trial of an AI-synthesized treatment for lung disease in late June.
I-Biotech Investment Signals a Shift in VC Spending The entrance of big-tech venture capitalists into pharma marks a notable shift in the flow of VC money. Earlier this year, Morgan Stanley predicted a $50 billion opportunity for AI in Big Pharma.
AI is also making its way into the finance industry. Find out how here.
But the industry is far from being a sure bet. In May, Benevolent AI, a London-based biotech startup, said it would lay off 180 staff after its main drug candidate failed.
Critics have also warned the technology is overhyped. Moreover, regulators like the US Federal Drug Administration have yet to approve a single AI-designed drug.
Got something to say about the development of AI-generated proteins and drugs by Inceptive or anything else? Write to us or join the discussion on our Telegram channel. You can also catch us on TikTok, Facebook, or X (Twitter).
Trusted Disclaimer
In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.
Share on Twitter
Share on Email
Share on Linkedin
Share on Google News
David-Thomas.jpg
David Thomas
READ FULL BIO
David Thomas graduated from the University of Kwa-Zulu Natal in Durban, South Africa, with an Honors degree in electronic engineering. He worked as an engineer for eight years, developing software for industrial processes at South African automation specialist Autotronix (Pty) Ltd., mining control systems for AngloGold Ashanti, and consumer products at Inhep Digital Security, a domestic security company wholly owned by Swedish conglomerate Assa Abloy. He has experience writing software in C,…
RELATED NEWS
Markets Analysis
Ripple (XRP) Holders Need to Do More Than Just Hope for Price Recovery
2 mins
6 hours ago
Markets Analysis
Shiba Inu Investors Turn Optimistic as 42% SHIB Supply Faces Losses
2 mins
8 hours ago
Markets News Report
UK Court Freezes Craig Wright’s Assets Amid $1.9 Million Legal Dispute
2 mins
9 hours ago
Markets Analysis
BONK Price Faces Potential Drawdown as Investors Turn Bearish
2 mins
10 hours ago
Markets News Report
Bitcoin Miners Face Profitability Challenges Amid Rising Production Costs
2 mins
12 hours ago
Top crypto projects in the US | July 2024
Harambe AI
Harambe AI
Explore
Uphold
Uphold
Explore
Exodus
Exodus
Explore
Coinbase
Coinbase
Explore
Chain GPT
Chain GPT
Explore
Most Read
Unpacking Polkadot Treasury Issues as Manta Co-Founder Speaks Up
3 mins
4 days ago
Why Is the Crypto Market Down Today?
2 mins
2 days ago
Vitalik Buterin Proposes New Model for Faster Ethereum Transactions
2 mins
5 days ago
The Next Altcoin Season Will Be Dominated by Meme Coins
3 mins
4 days ago
Want to know more?
Join our Telegram Group and get trading signals, a free trading course and daily communication with crypto fans!
JOIN OUR TELEGRAM
STAY UP TO DATE ON CRYPTO Join our newsletter SUBSCRIBE COMPANY About Us Our Authors Careers 🚀 Our Team PRODUCTS News Cryptocurrencies Exchanges Learn Newsletters NEW RESOURCES Advertise Remote Jobs Contact The Trust Project Verification Methodology © 2024 BeInNews Academy. Terms Privacy Disclaimer
ME: Please extract the article from this
[AI]: Former Google Employee Raises $100 Million to Bring AI to Big Pharma
In a significant move for the biotech and AI industries, Palo Alto-based startup Inceptive has secured a whopping $100 million in funding to pioneer the development of unique vaccine proteins utilizing artificial intelligence (AI). Spearheaded by former Google senior staff software engineer Jakok Uszkoreit, Inceptive aims to replicate and potentially surpass the groundbreaking success seen in mRNA vaccines like those deployed against COVID-19.
Jakob Uszkoreit, who has a notable background in working on large language models at Google, has outlined ambitious plans for his venture. Inceptive will focus on licensing the proteins created by its AI for use in clinical trials. Currently, the company has an impressive 310 pilots, ranging from pre-clinical to clinical development stages, earmarked for its novel approach. The strategic use of AI in designing proteins presents a paradigm shift, intending to instruct human body cells to execute specific functions, similar to running code on a computer. By the end of the decade, Uszkoreit predicts the emergence of around 700 mRNA-based drugs, highlighting the potential impact of AI in revolutionizing drug discovery and development.
Inceptive has not only attracted attention for its innovative approach but also for the caliber of its backers, with prominent Silicon Valley venture capitalists like Andreessen Horowitz and Nvidia Corporation's NVentures showing their support. NVentures, in particular, has previously invested $50 million in another promising drug discovery company, Recursion Pharmaceuticals, showcasing a keen interest in leveraging AI for medical advancements.
The collaboration with Nvidia provides Inceptive not just with funding but also access to cutting-edge tools, which will undoubtedly accelerate the startup's research and development efforts. This partnership is indicative of the broader industry trend where big-tech is increasingly converging with pharmaceutical science to explore new frontiers in medicine.
Such ventures are reshaping the way venture capital is being allocated, with an evident shift towards innovative solutions at the intersection of technology and healthcare. Morgan Stanley's forecast of a $50 billion opportunity for AI in Big Pharma underscores the high expectations and the burgeoning interest in this space. Nevertheless, challenges remain, as illustrated by the difficulties faced by companies like London-based Benevolent AI, which had to downsize significantly after its principal drug candidate faltered.
Criticism also persists regarding the overhype of AI's capabilities, alongside cautionary notes from regulatory bodies such as the US Federal Drug Administration (FDA), which has yet to approve any AI-designed drug. Despite these hurdles, the enthusiasm for AI in biotech, especially in projects like Inceptive's, continues to grow, driven by the potential for breakthroughs in drug discovery and the overarching goal of enhancing human health through innovation.
https://www.ft.com/content/dd557790-a39b-4fd1-8f18-c73532a61b3e
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/dd557790-a39b-4fd1-8f18-c73532a61b3e
Accessibility helpSkip to navigationSkip to contentSkip to footer
OPEN SIDE NAVIGATION MENU Subscribe Sign In MENU Financial Times Subscribe Sign In Artificial intelligenceAdd to myFT Former Google AI expert raises $100mn for biotech start-up Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’
The latest round of funding for Jakob Uszkoreit’s start-up has more than tripled its most recent valuation of $100mn, people close to the deal said Former Google AI expert raises $100mn for biotech start-up on x (opens in a new window) Former Google AI expert raises $100mn for biotech start-up on facebook (opens in a new window) Former Google AI expert raises $100mn for biotech start-up on linkedin (opens in a new window) Save Madhumita Murgia in LondonSEPTEMBER 6 2023 50 Print this page Stay informed with free updates Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox.
A biotech start-up founded by a former Google artificial intelligence expert has raised $100mn from Silicon Valley heavyweights Nvidia and Andreessen Horowitz as the market for generative AI applications expands into pharmaceuticals.
Palo Alto-based Inceptive plans to use the funds to develop new types of vaccines and drugs. It is designing “biological software” using the latest AI technology that was pioneered by the company’s founder Jakob Uszkoreit, who co-authored a paper that kick-started generative AI advances such as ChatGPT.
Software programs code executable instructions on a computer, he said. “We want to do that but with cells in your body.”
Inceptive is one of a new generation of start-ups which have collectively raised billions of dollars to apply AI to drug development. It is part of a race by Big Pharma and investors to capitalise on a $50bn market opportunity for AI in the sector, according to a Morgan Stanley report.
The two-year-old start-up was last valued at $100mn in 2021 after it raised seed funding of $20mn. The latest round, which includes new investors such as Obvious Ventures, more than triples Inceptive’s valuation, according to a source close to the deal.
The company has built an AI software platform that designs entirely unique molecules made of mRNA, the biological unit that Pfizer and BioNTech used to make their Covid-19 vaccines. Once Inceptive tests these in its labs, it licenses the molecules out to pharmaceutical companies to assemble and put through clinical trials.
Inceptive said it was working with a large European pharmaceutical company, which is experimenting with the start-up’s molecules to develop a new infectious disease vaccine. The success of mRNA against Covid-19 has yet to be replicated in other vaccines.
“We want to provide this as a horizontal capability to any entity developing mRNA and later RNA medicines,” Uszkoreit said. “There are currently about 310 programs in flight, somewhere between pre-clinical and clinical trials.”
He added that “conservative estimates” indicate more than 700 mRNA drugs will be in development by the end of the decade.
Other biotechs that have announced drugs discovered or developed using AI tools include Exscientia, Verge Genomics and Recursion Pharmaceuticals. However, most of the time and cost of the drug development process is in the clinical trials, rather than designing molecules.
Uszkoreit, who spent most of his career at Google working on AI research, has always been interested in the biological applications of machine learning. When he was at the US tech giant, he explored the use of AI to predict the structure of human proteins. His work on transformers ultimately led to breakthrough research by Google DeepMind, the London-based AI unit, which invented AlphaFold, an algorithm designed to predict the structure of almost every known protein.
“We want to maximise the positive impact of this type of work in AI,” he said.
Uszkoreit co-wrote the transformers research paper first published in June 2017. Since then, all of its co-authors have left Google, primarily to found their own start-ups as the race for generative AI talent heats up globally.
Recommended
The Big Read Transformers: the Google scientists who pioneered an AI revolution
NVentures, Nvidia’s venture capital arm, is one of Inceptive’s new investors and has backed a number of AI-focused start-ups in recent months. They include Israeli AI21 Labs, which is building its own large language model to compete with the likes of Google and OpenAI, and Aleph Alpha, a German competitor to OpenAI.
Nvidia recently invested $50mn in another AI-powered drug discovery platform Recursion, based in Utah. Inceptive’s funding from NVentures is an equity investment but also gives it access to some of Nvidia’s most cutting-edge computing platforms, including its latest chips, the company said.
Nvidia declined to comment.
Additional reporting by Hannah Kuchler
This article has been amended to correct the age of Inceptive
Copyright The Financial Times Limited 2024. All rights reserved. Reuse this content(opens in new window)CommentsJump to comments section Latest on Artificial intelligence Chinese politics & policy New podcast series: China’s race to tech supremacy
Undercover EconomistTim Harford AI has all the answers. Even the wrong ones
Inside BusinessRichard Waters The cloud over cloud companies
Nvidia Nvidia to make $12bn from AI chips in China this year despite US controls
Amazon Web Services Amazon to build $1.3bn Australian defence cloud
Special ReportAccelerating Business Generative AI turns spotlight on contract management
LexTechnology EQT can beat Aim market on a video gaming roll-up Premium content
Follow the topics in this article US & Canadian companies Add to myFT Tech start-ups Add to myFT Artificial intelligence Add to myFT Research and development Add to myFT Biotech Add to myFT Comments Useful links Support View Site Tips Help Centre Contact Us About Us Accessibility myFT Tour Careers Legal & Privacy Terms & Conditions Privacy Policy Cookie Policy Manage Cookies Copyright Slavery Statement & Policies Services Share News Tips Securely Individual Subscriptions Professional Subscriptions Republishing Executive Job Search Advertise with the FT Follow the FT on X FT Channels FT Schools Tools Portfolio FT App FT Digital Edition FT Edit Alerts Hub Business School Rankings Subscription Manager News feed Newsletters Currency Converter Community & Events FT Community FT Live Events FT Forums Board Director Programme More from the FT Group Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd. The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
ME: Please extract the article
[AI]: A former Google artificial intelligence expert, Jakob Uszkoreit, has successfully raised $100 million for his biotech startup, Inceptive, with significant investments from Silicon Valley giants like Nvidia and Andreessen Horowitz. This considerable sum aims to bolster Inceptive's efforts in creating new types of vaccines and drugs through the development of "biological software." This innovative approach leverages the latest AI technology, a field in which Uszkoreit has been a pioneering figure, especially recognized for his contributions to generative AI advancements such as ChatGPT.
Located in Palo Alto, Inceptive is carving out a niche in the burgeoning intersection of AI and drug discovery, a sector predicted by Morgan Stanley to represent a $50 billion market opportunity. The startup's valuation has soared beyond its previous $100 million mark in 2021, thanks to this latest funding round.
Utilizing an AI software platform, Inceptive is crafting unique mRNA molecule designs. These designs are then tested in labs and potentially licensed out to pharmaceutical companies for further development and clinical trials. Inceptive's work includes a collaboration with a major European pharmaceutical company to develop a new vaccine for infectious diseases, highlighting the potential for mRNA technology outside its notable success in Covid-19 vaccines.
Inceptive is positioned in a rapidly expanding field where AI's potential to streamline the long and costly drug development process is increasingly recognized. Jakob Uszkoreit's background at Google, particularly his role in AI research and exploring the use of AI in predicting the structure of human proteins, has laid a foundational understanding that drives Inceptive's mission.
The investment by NVentures, Nvidia’s venture capital arm, not only provides Inceptive with equity but also access to Nvidia's state-of-the-art computing platforms and chips. This partnership underscores the tech industry's ongoing interest and investment in AI-driven biotech innovations, recognizing the transformative potential of combining cutting-edge computational power with biological research and development.
https://www.crunchbase.com/organization/inceptive-5b4a
Search Crunchbase Search Crunchbase Inceptive Logo Inceptive Summary Financials People Technology Signals & News Similar Companies About Inceptive designs RNA molecules using large-scale deep learning in a tight loop with high-throughput experiments. Palo Alto, California, United States 11-50 Series A Private inceptive.life 1,435 Highlights Total Funding Amount Unlock for free Contacts 13 Employee Profiles 1 Investors 4 Similar Companies 15 Recent News & Activity News • Oct 30, 2023 Crunchbase News — How Former Googlers’ VC Firm Invests In Everything From LLMs To AI Doing Drug Discovery News • Oct 26, 2023 Crunchbase News — Andreessen Horowitz May Be Optimistic About Tech, But It’s Still Slowing Its Deal Pace News • Oct 11, 2023 Crunchbase News — Active Startup Investors Picked Up Their Pace Again In Q3 VIEW ALL Find More Contacts for Inceptive Engineer Non-Management Engineering 1 email found View contacts for Inceptive to access new leads and connect with decision-makers. Details Industries Biotechnology Life Science Medical Headquarters Regions San Francisco Bay Area, Silicon Valley, West Coast Founded Date 2021 Founders Jakob Uszkoreit, Rhiju Das Operating Status Active Last Funding Type Series A Also Known As Inceptive Nucleics Legal Name Inceptive Nucleics, Inc Company Type For Profit Contact Email info@inceptive.life Inceptive designs RNA molecules using large-scale deep learning in a tight loop with high-throughput experiments. They create tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Lists Featuring This Company
California Life Science Companies
Medical Early Stage Companies With Less Than $1B in Revenue
Private West Coast Companies (Top 10K)
Companies With Less Than $10M in Revenue (Top 10K) Frequently Asked Questions Where is Inceptive's headquarters? Inceptive is located in Palo Alto, California, United States. Who invested in Inceptive? Inceptive has 4 investors including Obvious Ventures and NVIDIA. How much funding has Inceptive raised to date? Inceptive has raised $120M. When was the last funding round for Inceptive? Inceptive closed its last funding round on Sep 7, 2023 from a Series A round. Who are Inceptive's competitors? Alternatives and possible competitors to Inceptive may include Eikon Therapeutics, Inceptive, and Vivodyne.
Unlock even more features with Crunchbase Pro Crunchbase Stay Connected Crunchbase News Subscribe to the Crunchbase Daily Who We Are Company Careers Partners Blog Press Contact Us What We Do Crunchbase Pro Marketplace Crunchbase Enterprise Data Licensing Customer Stories Pricing Helpful Links Create Profile Featured Lists and Searches The Crunchbase Difference Knowledge Center CA Privacy Notice Browse By: Organizations, People, Events Terms of Service | Privacy Policy | Sitemap | © 2024 Crunchbase Inc. All Rights Reserved. (086f756 735) Cookie Settings | Do Not Sell or Share My Personal Info
ME: Please extract the article from this
[AI]: Inceptive is a pioneering company located in Palo Alto, California, at the forefront of biotechnology and life sciences. Founded in 2021 by Jakob Uszkoreit and Rhiju Das, Inceptive stands out for its innovative approach to drug discovery and biotechnology development. Through the design of RNA molecules, the company harnesses the power of large-scale deep learning in conjunction with high-throughput experiments. This highly sophisticated process aims at developing more advanced biological software, paving the way for the creation of novel medicines and biotechnologies that were previously considered out of reach.
Operating under the legal name Inceptive Nucleics, Inc., this privately held company has secured its position in the competitive biotech industry by closing its last funding round on September 7, 2023, through a Series A investment. To date, Inceptive has raised a total of $120 million. Its ability to attract significant investment is a testament to the promising potential of its technology and approach to medicine development. Inceptive counts among its investors notable names such as Obvious Ventures and NVIDIA, underscoring the company's strong foundation and the industry's belief in its groundbreaking work.
Inceptive is strategically headquartered in the San Francisco Bay Area, placing it at the heart of the Silicon Valley innovation hub. With a team of 11 to 50 employees, the company is part of a vibrant ecosystem of tech and biotech innovators. Inceptive is known also by another name, Inceptive Nucleics, emphasizing its core focus on RNA research and nucleic acid technologies.
The company's mission centers around the use of deep learning algorithms and rapid experimental techniques to create powerful tools for the rational design of new, universally accessible cures and biotechnologies. This mission reflects a broader trend in the biotech industry towards leveraging artificial intelligence and computational methods to solve complex biological problems.
Inceptive's influence extends beyond the laboratory and investment realms into the media, as highlighted by its appearance in various news articles throughout October 2023. These articles showcase the interest and optimism surrounding venture capital investments in companies that are innovating at the intersection of artificial intelligence and drug discovery, positioning Inceptive as a key player in this rapidly evolving field.
Comparative analysis suggests that Inceptive's innovative approach places it among a select group of companies such as Eikon Therapeutics and Vivodyne, which are also striving to revolutionize biotechnologies and medical treatments. The shared goal among these competitors is to harness the power of technology to unlock new possibilities in healthcare and medicine, making previously untreatable conditions manageable and even curable.
Inceptive's contact information is readily available for those interested in learning more about its revolutionary work. With the company's contact email listed as info@inceptive.life, potential collaborators, investors, and researchers can easily reach out to explore opportunities for partnership and innovation. As Inceptive continues to grow and evolve, it stands as a beacon of hope in the quest for more effective, accessible, and innovative healthcare solutions.